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ABSTRACT
We are presenting here the first case of second primary endometrial stro-
mal sarcoma in a patient with colorectal carcinoma and reviewed the litera-
tur regarding metastasis patterns in colorectal carcinomas and the manag-
ment of endometrial stromal sarcomas. The differential diagnosis of colon 
cancer metastasis and second primary was of great importance in our case 
because the management and prognosis would differ fundamentally. The 
presumption that metastatic cancers are incureable, precludes the work-
up for detection of secondary cancers in most cases. This may hinder the 
proper treatment of patients. That is why the detection of secondary can-
cers should be strongly encouraged especially in cases with an unexpected 
metastasis pattern.
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KOLOREKTAL KANSER SEYRİ SIRASINDA İKİNCİ PRİMER OLARAK GELİŞEN 
ENDOMETRİAL STROMAL SARKOMA OLGUSU: LİTERATÜRÜN GÖZDEN 
GEÇİRİLMESİ
ÖZET
Literatürde kolorektal kanser seyri sırasında ilk defa saptanan endometrial 
stromal sarkom olgusunu sunuyoruz. Olgumuzda kolon kanseri metastazı 
ve ikinci primer arasında ayırım yapabilmek çok önemliydi, çünkü prognoz 
bilgileri ve tedavi yöntemleri tamamen değişmekteydi. Metastatik kanserin 
şifa olmayacağı önyargısı, çoğu zaman ikinci pirimer çalışmalarının yapıl-
masını ve hastaların doğru tedavilere ulaşmasını engellemektedir. Bu ne-
denle özellikle alışılmadık metastaz tablolarında ikinci primer araştırmaları 
mutlaka yapılmalı ve  karar verilene kadar ısrarla tekrarlanmalıdır.
Anahtar sözcükler: kolorektal kanser, endometriyal stromal sarkom, ikinci primer
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A 52 years old woman was diagnosed with pT3N1M0 colorectal adenocarcinoma after a hemicolecto-my. Postoperative PET/CT evaluation revealed 
several abdominal lymph nodes measuring about 1 cm 
in diameter, with an SUV value of 5.7 and a mass inher 
uterus consistent with myoma uteri. She was under fol-
low-up care for her myoma uteri for the past seven years. 
She was started on adjuvant chemotherapy with FOLFOX 
with close follow-up for these suspicious lymph nodes. 
Interim PET/CT evaluation after three months revealed no 
other pathologic finding besides her known mass in the 
uterus. Her adjuvant chemotherapy was completed. The 
last PET/CT evaluation in March 2013 revealed multiple 
mediastinal and intrabdominal lymph nodes with an SUV 
of 4.4-6.5 and a mass in the right iliac bone with a diame-
ter of 27.5 mm and an SUV of 14.6.
The case was discussed at the tumor board. This clinical 
picture suggested a second primary cancer, so an inter-
ventional radiologist was requested for a biopsy of the 
new lesions. The location of the lymph nodes precluded 
their sampling. So a trucut bone biopsy was performed 
first which revealed an inflamatory reaction. An abdom-
inal MRI was performed to see the uterine mass better. 
The lobulated mass was hypointense in the T1 series and 
hyper-intense the T2 series and its radio-contrast uptake 
pattern suggested a sarcoma. In Mai 2014 a total hysterec-
tomy, bilateral salphingo-oopherectomy and abdominal 
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lymph node sampling were performed. The pathologic 
examination revealed a low-grade endometrial stromal 
sarcoma (Desmin, SMA, Pan-CK, S100, CD34, CD117, EMA, 
ER, PR negativE., CD10 ve Cyclin D1 positive; Ki67 index: 
%25; no tumor necrosis, mitosis <10/10HPF; T:13 cm).
Because of a lack of estrogen and progesteron positivity 
in her tumor specimen, hormonal therapy was not done. 
She experienced severe coughing due to a lung nodule 
above the diaphram so she was started on palliative che-
motherapy for her metastatic sarcoma consisting of doxo-
rubicine and ifosphamide. She did not respond well to 
two cycles of chemotherapy.
Discussion
Colorectal carcinoma remains the third most common 
cancer among adult men and women and is the third 
most common cause of death from cancer (1). It is well 
recognized that colorectal cancer does not frequently 
metastasize to bone. The incidence of bone metastasis in 
colerectal cancer is reported to be about 10%. The most 
common sites of metastases are the liver and the lungs. 
Solitary bone metastases and bone metastasis at presen-
tation are very uncommon (2). Liver metastases preceede 
lung metastases in most cases. A retrospective study 
evaluated 252 patients regarding the metastasis pattern 
in colorectal carcinoma. Analysis of metastasis to bone 
showed that 14 of the 252 individuals (5.5%) had bone 
lesions and no individuals had metastasis only to bone at 
the time of diagnosis. In all patients that developed bone 
metastasis, liver and/or lung metastasis was always pres-
ent first. One individual presented with bone lesions at 
the time of diagnosis; however, liver metastasis was also 
present (3).
Endometrial stromal sarcomas (ESS) are rare malignant 
tumors of the uterus, and most of the information avail-
able in literature is based on small series or case reports 
(4). Although the main tumor mass is almost always in-
tramyometrial, most ESS involve the endometrium and 
uterine curettage which may be helpful in preoperative 
diagnosis(5, 6). However, when the lesion is completely 
within the myo-metrium, the scrapings may not be help-
ful. Due to the great similarity between ESS and normal 
endometrium, it may be impossible to diagnose it with 
certainty on curettage fragments, and the definitive diag-
nosis can be made only on a hysterectomy specimen.
Strong and/or diffuse positivity for CD10 is found in ESS, 
which is helpful in distinguishing these tumors from his-
tological mimics like cellular leiomyoma, that are general-
ly negative (7). ESS is positive for both estrogen and pro-
gesterone receptors in most cases.
As for other sarcomas, surgery is the most effective treat-
ment for ESS. The efficacy of adjuvant therapy is not prov-
en. Survival in patients with undifferentiated endometrial 
sarcoma (previously called high-grade endometrial stro-
mal sarcoma) appears to be related to the extent of re-
sidual disease after initial surgery and would suggest the 
necessity for aggressive cytoreduction as a main modality 
of treatment. However, the role of debulking surgery for 
ESS (formally known as “low-grade ESS”) remains unclear 
(8). Recurrent ESS has been treated with hormone thera-
py, radiation, surgical re-excision, or a combination of two 
or more of these modalities (9). There are few case reports 
where the recurrent ESS was treated wit hetoposide, cy-
clophosphamide, and doxorubicin (10). Even though che-
motherapy is a mode of treatment in undifferentiated en-
dometrial sarcoma, data supporting their efficiency in the 
case of recurrence of ESS are limited. Because of the large 
variation in pathologic characteristics, combined with a 
scarcity of patients, there is insufficient information about 
optimal management.
Conclusion
We presented here the first case of second primary en-
dometrial stromal sarcoma in a patient with colorectal 
carcinoma. In our case, the differential diagnosis of colon 
cancer metastasis and second primary cancer was of great 
importance because the treatment and prognosis is dif-
ferent. The preassumption that metastatic cancers are in-
curable precudes the work-up for detection of secondary 
cancers in most cases. This may hinder the proper treat-
ment of patients. That is why the detection of secondary 
cancers should be strongly encouraged especially in cases 
with an unexpected metastasis pattern.
Metastasis or Second Primary?
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